Inc. (NASDAQ:INCR) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition.
Certain portions of our press release dated July 26, 2017, a copy of which is annexed hereto as Exhibit no. 99.1, are incorporated by reference herein, and are filed to this Item 2.02. They are as follows:
| ● | Portions of the 1st paragraph relating to sales for the second quarter of 2017 |
| ● | The 2nd paragraph (consisting of a table) relating to sales for the second quarter and the first six months of 2017 |
| ● | The 3rd and 4th paragraphs relating to sales of European Operations for the second quarter of 2017 |
| ● | Portions of the 6th paragraph relating to sales of United States Operations for the second quarter of 2017 |
Item 7.01. Regulation FD Disclosure.
Certain portions of our press release dated July 26, 2017, a copy of which is annexed hereto as Exhibit no. 99.1, are incorporated by reference herein, and are filed to this Item 7.01 and Regulation FD. They are as follows:
| ● | The last sentence of the 1st paragraph relating to the plans to issue results for the second quarter of 2017 on or about August 7, 2017 |
| ● | The 5th paragraph relating to the extension of the Paul Smith license agreement |
| ● | Portions of the 6th paragraph relating to the anticipated product launches for U.S. operations in the second half of the year |
| ● | The 7th paragraph relating to 2017 guidance |
| ● | The 9th paragraph relating to forward looking information |
| ● | The balance of such press release not otherwise incorporated by reference in Item 2.02 |
Item 9.01 Financial Statements and Exhibits.
| ● | 99.1 Our press release dated July 26, 2017 |
INTER PARFUMS INC ExhibitEX-99.1 2 s106911_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE INTER PARFUMS,…To view the full exhibit click here
About Inc. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. Inc. (NASDAQ:INCR) Recent Trading Information
Inc. (NASDAQ:INCR) closed its last trading session down -0.30 at 56.40 with 648,767 shares trading hands.
